FDA peptides rules could narrow which peptides pharmacies are allowed to make—and put peptide-screening assistants in the crosshairs. AI can compare candidates before experiments, but humans still have to run tests and assess safety. The immediate evidence is regulatory scope: fewer compounds can move through pharmacy workflows without added scrutiny. So who goes first—AI assistants or human screening teams? Pick a side in the comments; staying silent is how the next reorg gets explained for you.
